Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?

NCT ID NCT06105931

Ongoing Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study aims to measure heart and metabolic risk markers—such as insulin resistance and fat distribution—in young adults aged 18 to 30 with type 1 diabetes and a body mass index under 25. Researchers will track changes over one year using glucose clamps and meal tests. The goal is to create a reference for how close obesity treatments can bring these markers to normal levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could provide a reference for how close GLP-1 obesity treatments bring cardiometabolic risk markers in people with type 1 diabetes to normal levels.
What could go wrong: This is a small, early-phase observational study with only 15 participants, so results may not apply broadly. It does not test any treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY TYPE1DIABETES

Contacts and locations

Show contact details

Locations

Yale Pediatric Diabetes Research

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.